Naive T cells require two distinct signals to proliferate and differentiate into armed effector cells. Signal 1 is Ag-specific and generated by interaction of the TCR with antigenic peptide associated with MHC molecules on APC. Signal 2 is referred to as costimulatory because, while essential, it does not by itself induce any functional response in T cells. The most well characterized costimulatory signal is generated through the interaction of the T cell molecule CD28 with its ligands B7-1 and B7-2 on APC ([@B1]).

Negative costimulation also plays an important role in the regulation of T cell activation and peripheral T cell homeostasis. Interaction of B7 with cytotoxic T lymphocyte--associated antigen 4 (CTLA-4), expressed on activated T cells, mediates a negative signal that inhibits T cell proliferation ([@B2]). The importance of CTLA-4 in T cell proliferation is highlighted by the phenotype observed in CTLA-4--deficient mice, which is characterized by CD4^+^ T cell--driven polyclonal expansion of peripheral T cells, multiorgan lymphocytic infiltration, and death at three to four weeks of age ([@B3]--[@B5]).

In vitro, signals mediated by CTLA-4 decrease IL-2 production and IL-2 receptor expression and inhibit cell cycle progression (for review, see reference [@B2]). In vivo, CTLA-4 signaling can be blocked by administration of anti--CTLA-4 mAb, resulting in enhanced T cell immune responses to Ag ([@B6]) or superantigen ([@B7]). Similarly, Th2-type immune responses to nematode parasite infection ([@B8]) and Th1-type immune responses to mycobacteria can be augmented by anti--CTLA-4 treatment (Kirman, J., K. McCoy, S. Hook, M. Prout, B. Delahunt, I. Orme, A. Frank, and G. Le Gros, manuscript submitted for publication), and autoimmune conditions are exacerbated ([@B9]--[@B11]). Antitumor immune responses are also augmented by preventing CTLA-4 function ([@B12]), as demonstrated by the enhanced tumor rejection in mice treated with anti--CTLA-4 mAb.

In this study, we have sought to define a potential mechanism for anti--CTLA-4--induced tumor immunity. We have reasoned that a B7-expressing cell must be involved, presenting tumor antigen and providing ligands for CTLA-4 on T cells and thus inducing incomplete or transient activation of antitumor T cells. Current understanding suggests that this cell is a dendritic cell (DC). Anti--CTLA-4 mAb may enhance the activation of Ag-specific CD8^+^ T cells via DC by either directly preventing the engagement of CTLA-4 on CD8^+^ T cells or enhancing CD4^+^ helper function. We find that anti--CTLA-4 treatment significantly enhances the expansion and cytotoxic activity of CD8^+^ T cells activated by Ag on DC and that this enhancement can occur independently of CD4^+^ T cell help.

Materials and Methods
=====================

Mice.
-----

C57BL/6 mice were obtained from The Jackson Laboratory. Strain 318 TCR-transgenic mice ([@B13]) were provided by Prof. H. Pircher (University of Freiburg, Freiburg, Germany) and B6Aa^0^/Aa^0^ (MHC class II^−/−^) mice ([@B14]) by Dr. H. Blüthmann (Hoffmann-La Roche, Basel, Switzerland). All mice were bred and maintained at the Biomedical Research Unit of the Wellington School of Medicine.

In Vitro Culture Media and Reagents.
------------------------------------

Cultures were in IMDM and additives were as described ([@B8]). The lymphocytic choriomeningitis virus glycoprotein peptide KAVYNFATM (LCMV~33--41~) was obtained from Chiron Mimotopes. Supernatant from the cell line IL2L6 was used as a source of human rIL-2.

Antibodies and FACS^®^ Staining.
--------------------------------

Anti--CTLA-4 clone UC10-4F10-11 (provided by Dr. J. Bluestone, University of Chicago, Chicago, IL), anti-CD3 (145-2C11), anti-CD28 (37.51), anti-CD8 (2.43), anti-CD4 (GK1.5), anti-CD11c (N418), anti-FcγRII (2.4G2), anti-Vβ8.1/8.2 (KJ16.133.18), and anti-CD44 (I42/5) were affinity purified from culture supernatants using protein G--Sepharose (Pharmacia Biotech) and conjugated to FITC or biotin. Anti-Vα2--PE mAb and streptavidin--Cy-Chrome were obtained from PharMingen. Control IgG was affinity purified from hamster serum using protein G--Sepharose. Cells were stained in PBS containing 2% FCS and 0.01% sodium azide as described ([@B15]).

In Vitro CTLA-4 Cross-linking Experiments.
------------------------------------------

Lymph node cell suspensions were layered onto a Percoll gradient (Pharmacia Biotech AB) and the high density cells taken from the interface of 60 and 70% Percoll layers. CD4^+^ and Ig^+^ cells were depleted by treatment with anti-CD4 mAb followed by anti-Ig magnetic bead adherence (Dynal A.S.). The remaining cell suspension contained 95% CD8^+^ T cells, with no detectable CD4^+^ T cells and \<2% B220^+^ cells. For cross-linking experiments, 10^5^ resting CD8^+^-enriched cells were cultured with 10^5^ polystyrene beads coated with anti-CD3 and either anti--CTLA-4 or control IgG in the presence or absence of soluble anti-CD28 as described ([@B16]). Control cultures were provided with 50 U/ml human rIL-2. Proliferation was determined by ^3^H-TdR incorporation over the last 8 h of a 72-h culture.

Culture of Bone Marrow--derived DC and Ag Loading.
--------------------------------------------------

Bone marrow cells from C57BL/6 mice or MHC class II^−/−^ mice were cultured in 20 ng/ml IL-4 and 20 ng/ml GM-CSF for 6--8 d as described ([@B17]). Cultures typically contained 90--100% DC as determined by FACS^®^ staining with anti-CD11c mAb. DC were loaded with Ag by incubation in medium containing 10 μM LCMV~33--41~ for 2 h.

Adoptive Transfer and Immunization.
-----------------------------------

Lymph node cell suspensions were prepared from line 318 mice, and the percentage of T cells expressing transgenic TCR was determined by flow cytometry using anti-TCR Vα2 and anti-TCR Vβ8.1/8.2 mAb. The equivalent of 3--5 × 10^6^ Vα2^+^Vβ8^+^ T cells were injected intravenously into C57BL/6 recipients, and on the same day, mice were given an intraperitoneal injection of 1 mg anti--CTLA-4 mAb or control IgG. 1 d later, recipients were immunized by subcutaneous injection of 10^5^ LCMV~33--41~ peptide--loaded DC or untreated DC in IMDM. For each experiment, a group of adoptive transfer recipients was left unmanipulated to serve as a control. For experiments in MHC class II^−/−^ recipients, the donor cell preparations were depleted of CD4^+^ and Ig^+^ cells as described above.

Direct Cytotoxicity Assays.
---------------------------

C57BL/6 mice received TCR-transgenic T cells, were treated with anti--CTLA-4 or control IgG, and were immunized with 3 × 10^4^ DC as described above. 7 d after DC immunization, splenocytes were harvested, depleted of CD4^+^ and Ig^+^ cells, and tested for cytotoxic activity in vitro by JAM test on 5,000 labeled EL4 cells that had been incubated in the presence or absence of 1 μM LCMV~33--41~ peptide for 1 h at 37°C before the assay ([@B18]). All cultures were performed in triplicate.

Results
=======

CTLA-4 Mediates a Negative Regulatory Signal to Purified CD8^+^ T Cells In Vitro.
---------------------------------------------------------------------------------

We used anti--CTLA-4 mAb conjugated to polystyrene beads to examine the effect of CTLA-4 cross-linking on the activation and proliferation of purified resting CD8^+^ T cells in culture. Lymphocyte preparations from line 318 TCR-transgenic mice were depleted of CD4^+^ and Ig^+^ cells using Ab-coated magnetic beads. Enriched CD8^+^ T cells were cultured with beads coated with either anti-CD3 and anti--CTLA-4 or anti-CD3 and control IgG in the presence of a positive costimulatory signal provided by soluble anti-CD28. As shown in Fig. [1](#F1){ref-type="fig"} A, after 24 h both control Ab--treated and anti-- CTLA-4--treated cultures contained activated CD8^+^ T cells with markedly increased expression of the activation markers CD25 and CD69 as compared to resting cells. However, whereas expression of these activation markers was maintained until after 48 h in control cultures, it was rapidly lost in the presence of anti--CTLA-4. No increase in cell death was apparent in anti--CTLA-4--treated cultures as compared to control cultures (data not shown). Proliferation of CD8^+^ T cells in these cultures was assayed 64--72 h after activation (Fig. [1](#F1){ref-type="fig"} B). In the presence of anti-CD28, control cultures were highly activated and showed significant levels of proliferation. In contrast, cross-linking of CTLA-4 with mAb-conjugated beads completely inhibited proliferation. The inhibitory function of anti--CTLA-4 was overridden by addition of exogenous IL-2. Therefore, the proliferative function of CD8^+^ T cells can be directly inhibited by signals mediated via CTLA-4. Similar results have been reported by Walunas et al. using CD8^+^ T cells from the TCR-transgenic strain 2C ([@B19]).

Anti--CTLA-4 mAb Treatment In Vivo Enhances DC-induced CD8^+^ T Cell Activation and Accumulation.
-------------------------------------------------------------------------------------------------

To determine whether CTLA-4 signals regulate the activation of CD8^+^ T cells in vivo, we examined the effect of a neutralizing anti-- CTLA-4 mAb on the accumulation of specific CD8^+^ T cells in the lymph nodes of mice immunized with Ag-loaded DC. An adoptive transfer model was used ([@B15]) in which nonmanipulated C57BL/6 hosts received 5 × 10^6^ TCR-transgenic T cells from strain 318 mice. These T cells are specific for LCMV~33--41~ in association with H-2D^b^ and can be identified by their Vα2^+^Vβ8^+^CD8^+^ phenotype. Anti-- CTLA-4 mAb or control IgG was administered intraperitoneally at the time of adoptive transfer, followed by DC loaded with LCMV~33--41~ peptide on day 1. Control animals received either DC that had not been loaded with Ag or no DC immunization at all. Activation and accumulation of Vα2^+^Vβ8^+^CD8^+^ T cells in the draining lymph nodes were examined on day 5 after immunization, as preliminary experiments showed that both responses were maximal on this day (data not shown). The data in Fig. [2](#F2){ref-type="fig"} are presented as fold increase in the total number of Vα2^+^Vβ8^+^CD8^+^ T cells in immunized mice over the number of the same cells in animals that were not immunized. This is because the fold increase in Vα2^+^Vβ8^+^CD8^+^ T cells was reproducible in different experiments, whereas the absolute cell number varied. In control IgG--treated animals, an average 2.4-fold increase in the number of Vα2^+^Vβ8^+^CD8^+^ T cells was observed in response to Ag-loaded DC, whereas immunization with DC without Ag failed to induce any increase. Significantly, when animals were treated with anti--CTLA-4 mAb, the Ag-induced accumulation was greater, with an average sixfold increase observed. This reflected both an increase in the proportion of Vα2^+^Vβ8^+^CD8^+^ T cells and an increase in the total number of lymph node cells (twofold). Immunization with Ag-loaded DC induced increased CD44 expression on a significant proportion of Vα2^+^Vβ8^+^ T cells, and this proportion was greatly increased in animals treated with anti--CTLA-4 mAb (Fig. [2](#F2){ref-type="fig"}). Importantly, increased CD44 expression was strictly Ag dependent and was not detected on cells not expressing the Vα2^+^Vβ8^+^ receptor. Interestingly, a twofold increase in the cellularity of the draining lymph node, with no increase in the percentage of Vα2^+^Vβ8^+^CD8^+^ cells, was observed in mice treated with anti--CTLA-4 and immunized with DC only, resulting in an increase in the absolute number of Vα2^+^Vβ8^+^ cells. The increased cellularity was immunization related, as it was not observed in nondraining lymph nodes. No increased expression of CD44 or other activation markers was observed on these Vα2^+^Vβ8^+^ cells (not shown), indicating that blockade of CTLA-4 signals was not sufficient to induce T cell activation in the absence of Ag. Taken together, these results suggest that inhibition of CTLA-4--mediated signaling results in enhanced Ag-specific proliferation of CD8^+^ T cells in vivo.

Enhanced CD8^+^ T Cell Activation In Vivo by Anti--CTLA-4 mAb Treatment Is Not a Result of Increased CD4^+^ T Helper Function.
------------------------------------------------------------------------------------------------------------------------------

It was possible that the enhanced CD8^+^ T cell activation induced by anti--CTLA-4 mAb treatment was due to increased helper function of CD4^+^ T cells. To examine this possibility, we repeated the DC immunization experiments using MHC class II^−/−^ DC, which are unable to present Ag to CD4^+^ T cells and elicit T cell help. MHC class II^−/−^ mice were also used as immunization recipients, as in these mice, no T cell help would be available if Ag was transferred from the injected DC to host APC.

As shown in Fig. [3](#F3){ref-type="fig"}, immunization with MHC class II^−/−^ DC loaded with LCMV~33--41~ peptide induced selective accumulation of Vα2^+^Vβ8^+^CD8^+^ T cells in the draining lymph nodes of MHC class II^+/+^ and MHC Class II^−/−^ mice. More importantly, treatment with anti--CTLA-4 mAb significantly enhanced the accumulation of Vα2^+^Vβ8^+^CD8^+^ T cells (Fig. [3](#F3){ref-type="fig"}) and their expression of CD44 (not shown), regardless of the expression of MHC class II on host APC. Again, as for Fig. [2](#F2){ref-type="fig"}, treatment with anti--CTLA-4 caused an increase in the cellularity of the draining lymph node in mice immunized with DC only; however, the percentage of Vα2^+^Vβ8^+^CD8^+^ cells was not increased compared to controls nor was their expression of activation markers altered. These results suggest that the enhanced accumulation of Vα2^+^Vβ8^+^ T cells observed with anti--CTLA-4 treatment in DC-immunized mice is not dependent on the provision of CD4^+^ T cell help. We conclude that CD8^+^ T cells can be directly regulated in vivo by signals mediated via CTLA-4 molecules.

Anti--CTLA-4 mAb Treatment In Vivo Enhances Ag-specific Cytotoxicity Measured In Vitro.
---------------------------------------------------------------------------------------

To determine whether in vivo treatment with anti--CTLA-4 mAb affects the effector function of CD8^+^ T cells, we assayed cytotoxic activity in mAb-treated adoptive transfer recipients that had been immunized with DC. Spleen cells were recovered 7 d after immunization, depleted of CD4^+^ T cells and Ig^+^ cells, and assayed directly on LCMV~33--41~ peptide--coated EL4 targets. As is seen in Fig. [4](#F4){ref-type="fig"}, Ag-specific cytotoxicity was barely detectable when CD8^+^ effector cells were prepared from DC-immunized, control IgG--treated mice. Therefore, the cytotoxic activity induced by DC immunization was below the threshold of detection by this technique. In contrast, in vivo treatment with anti--CTLA-4 mAb resulted in a measurable increase in specific cytotoxicity, with 50% lysis observed at an E/T ratio of 150:1 when MHC class II^+/+^ DC were used for immunization. When MHC class II^−/−^ DC were used, 35% lysis was observed. Increased cytotoxic activity of effector CD8^+^ T cells in the anti--CTLA-4--treated groups was apparent even when the E/T ratios were adjusted for the percentage of Vα2^+^Vβ8^+^ cells (data not shown). These results indicate that CTLA-4--mediated signals regulate the cytotoxic activity of CD8^+^ T cells, also in the absence of CD4^+^ help.

Discussion
==========

In this paper, we show that CD8^+^ T cell responses induced by Ag presented on DC are amplified when CTLA-4--dependent signaling is inhibited in vivo. While anti-- CTLA-4 mAb treatment was known to enhance several kinds of T cell immune responses ([@B6]--[@B11]), it had not been previously reported that increased CD8^+^ T cell activation is also observed when DC are used as APC, a finding that may have significant implications for the use of anti-- CTLA-4 in tumor immunotherapy.

We investigated whether anti--CTLA-4 enhanced the activity of CD8^+^ T cells directly or by increasing the availability of CD4^+^ T cell help. To this purpose, we carried out experiments in which the potential contribution of CD4^+^ T cells to the CD8^+^ T cell response was progressively reduced. We observed augmented CD8^+^ T cell responses regardless of the availability of CD4^+^ T cells, indicating that CD4^+^ T cells were not critical to the observed effect. As also reported by Walunas et al. ([@B19]), a purified cell culture system confirmed that CD8^+^ T cells could respond directly to CTLA-4--mediated signals in vitro. However, although it is clear that the effects of anti--CTLA-4 we have observed are independent of CD4^+^ T cell help, CD4^+^ T cells are thought to be necessary for the activation of DC and for the productive development of a CD8^+^ T cell response ([@B20]). Because we could observe good CD8^+^ T cell responses even in the absence of CD4^+^ T cells, we must conclude that our DC were sufficiently activated before injection to be able to induce good CD8^+^ T cell priming.

The findings reported in this paper are relevant to the described enhancement of tumor immunity induced by in vivo treatment with anti--CTLA-4 mAb ([@B12]). Treatment with anti--CTLA-4 mAb in vivo is thought to block the delivery of a negative signal, mediated by B7 ligands on B7-expressing cells. Because tumor cells are generally B7^−^, a third cell type must be providing B7 in this system. Bone marrow--derived APC, presumably DC, have been reported to take up and present self Ag ([@B21]) as well as tumor Ag ([@B22]) from peripheral tissues in physiological situations. We thus hypothesized that tumor immunity induced by anti--CTLA-4 treatment is most likely due to enhanced T cell activation by tumor antigen presented by DC. In this paper, we show that both CD8^+^ T cell activation and specific cytotoxic activity induced by immunization with DC are amplified in the presence of anti--CTLA-4 mAb, possibly resulting in the tumor immunity described by Leach et al. ([@B12]). Our results also imply that tumors in which Ag fails to gain access to a DC, because of either poor antigenicity or limited DC presence in the tumor, may fail to respond to anti--CTLA-4 treatment. Conversely, manipulations which increase local inflammation and therefore access of tumor Ag to DC ([@B23]), or tumor vaccination procedures, could become more effective if used in combination with anti--CTLA-4 treatment ([@B24]).

As in the case of CTLA-4--deficient mice ([@B25]), we could observe no spontaneous T cell activation in the absence of Ag when CTLA-4 signaling was blocked. Surprisingly, however, we observed that lymph node cellularity was increased by anti--CTLA-4 treatment even after immunization with DC only. This increase was restricted to the draining lymph nodes, indicating that it was immunization related. DC have been reported to induce Ca^2+^ responses in T cells in the absence of Ag ([@B26]). This low level of stimulation may be amplified by the removal of CTLA-4 signals.

In conclusion, blockade of CTLA-4 directly enhances the ability of CD8^+^ T cells to respond to Ag presented on DC, amplifying their expansion and accumulation in lymphoid organs and their cytotoxic activity. This finding may help explain the antitumor effect of anti--CTLA-4 mAb treatment, and, if extended to CD4^+^ T cells, the autoimmune phenotype observed in CTLA-4--deficient mice.
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###### 

Cross-linking of surface CTLA-4 molecules inhibits activation and proliferation of purified CD8^+^ T cells. Resting CD8^+^ T cells were isolated from the lymph nodes of line 318 transgenic mice and cultured with sterile polystyrene beads coated with either anti-CD3 and anti--CTLA-4 or anti-CD3 and control hamster IgG. Cultures were provided either no costimulus, soluble anti-CD28, or soluble anti-CD28 and rIL-2. (A) Expression of the activation markers CD25 and CD69 on resting CD8^+^ T cells and on CD8^+^ T cells cultured in the presence (thick line) or absence (dotted line) of anti--CTLA-4. (B) ^3^H-TdR uptake by CD8^+^ T cells cultured in the same conditions, measured 72 h after stimulation. Results are shown as the average of triplicate wells ± SE.
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###### 

Treatment with anti--CTLA-4 mAb augments the accumulation and activation of adoptively transferred CD8^+^ T cells in the lymph nodes of mice immunized with DC. (A) Numbers of Vα2^+^Vβ8^+^CD8^+^ cells were determined in the lymph nodes of experimental mice (*n* = 4--8) 5 d after immunization with DC and are presented as the average ± SE fold increase in the total number of Vα2^+^Vβ8^+^CD8^+^ T cells over the corresponding nonimmunized adoptive transfer controls. Combined results from two experiments are shown. Numbers of Vα2^+^Vβ8^+^CD8^+^ T cells in nonimmunized adoptive transfer controls varied between 3 × 10^4^ and 10^5^ over two different experiments. Mice received treatment with anti--CTLA-4 mAb or control IgG as indicated. (B) Representative stainings from mice immunized with DC + Ag. CD44 expression on gated Vα2^+^Vβ8^+^ cells was determined by triple staining and FACS^®^ analysis.
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###### 

Treatment with anti--CTLA-4 mAb augments the accumulation of CD8^+^ T cells in the lymph nodes of immunized mice regardless of the availability of T cell help. Groups of C57BL/6 (A) or MHC class II^−/−^ (B) recipient mice (*n* = 4--11) received 5 × 10^6^ Vα2^+^Vβ8^+^CD8^+^ T cells from line 318 transgenic donors, were treated with either anti--CTLA-4 mAb or control IgG, and were immunized with MHC class II^−/−^ DC as described in the Fig. [2](#F2){ref-type="fig"} legend. Combined data are shown as for Fig. [2](#F2){ref-type="fig"}. The number of Vα2^+^Vβ8^+^CD8^+^ T cells in nonimmunized adoptive transfer controls varied between 3 × 10^4^ and 1.5 × 10^5^ over three different experiments for the data in A and between 1.9 × 10^4^ and 2.4 × 10^4^ over two different experiments for the data in B.
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![Treatment with anti--CTLA-4 mAb during in vivo immunization with DC enhances the direct, Ag-specific cytotoxicity measured in vitro. C57BL/6 recipient mice received 5 × 10^6^ Vα2^+^Vβ8^+^CD8^+^ T cells from line 318 transgenic donors, were treated with either control IgG or anti--CTLA-4 mAb, and were immunized with 3 × 10^4^ LCMV~33--41~ peptide--loaded DC from C57BL/6 or MHC class II^−/−^ mice as described for Fig. [2](#F2){ref-type="fig"}. 7 d after immunization, spleen cell suspensions were prepared and depleted of CD4^+^ T cells and Ig^+^ cells by magnetic adherence. Cytotoxic activity was measured in vitro by JAM test on EL4 targets or on EL4 + LCMV~33--41~ peptide.](JEM981663.f4){#F4}
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